This study is for NON-HOSPITALIZED COVID-19 infected patients. The study is single infusion of monoclonal antibody (2 doses) vs Placebo as investigational treatment. Patients will be randomized 1:1:1.
Summary Inclusions for the study are:
- Age 18 years and over
- Covid PCR Positive (on-site testing can also confirm within 45 min)
- One more more of SOB, cough or fever
- COVID Symptoms for less than 7 days
- Able to consent
Summary Exclusions for the study are:
- Hospital admission for COVID
- IVIG infusion in past 3 months
- Treatment with Remdesivir
- Pregnant/Breastfeeding